Suppr超能文献

使用创新的药物类别评分工具进行年度处方集优先审查。

Use of an Innovative Pharmaceutical Class Scoring Tool for Prioritized Annual Formulary Review.

作者信息

Sheldon Holly, Kostrzewa Audrey, Werner Shannon, Audley Terry, Biggs Adam, Mancuso Taylor, Picone Mary Frances

机构信息

Froedtert & the Medical College of Wisconsin.

Concordia University Wisconsin.

出版信息

Innov Pharm. 2022 Dec 12;13(2). doi: 10.24926/iip.v13i2.4785. eCollection 2022.

Abstract

Though The Joint Commission requires health systems perform annual formulary review, guidance for how to perform this review is lacking. Published methods include comprehensive review of all pharmaceutical classes; however, this approach may not be the most efficient or effective option for a health system with a large formulary. To create a prioritization system for annual formulary review through development of a pharmaceutical class scoring tool. Drug information pharmacists developed the scoring tool, which used external and internal data to score pharmaceutical classes in 4 categories: safety, efficacy, cost, and utilization. The primary outcome, number of formulary changes resulting from pharmaceutical class review, was compared between the highest-scoring and lowest-scoring class to assess the tool's ability to prioritize high-yield class reviews. The tool calculated scores for 91 pharmaceutical classes, altogether containing 962 medications. After review of the highest-scoring class, corticosteroids, 2 formulary changes were made: one dosage form was removed from formulary, and one medication was restricted to outpatient use only. Zero formulary changes resulted from review of the lowest-scoring class, pharmaceutical adjuvants. The tool described in this study prioritized annual formulary review efforts by identifying a pharmaceutical class with meaningful formulary optimization opportunities as the highest-scoring class, while correctly identifying a class with no optimization opportunities as the lowest-scoring class.

摘要

尽管联合委员会要求医疗系统进行年度药品目录审查,但缺乏关于如何进行此项审查的指导。已公布的方法包括对所有药物类别进行全面审查;然而,对于拥有大量药品目录的医疗系统而言,这种方法可能并非最有效或高效的选择。通过开发一种药物类别评分工具来创建年度药品目录审查的优先排序系统。药物信息药师开发了该评分工具,该工具使用外部和内部数据对药物类别在四个类别中进行评分:安全性、有效性、成本和使用情况。将得分最高和最低的类别之间因药物类别审查导致的药品目录变更数量这一主要结果进行比较,以评估该工具对高收益类别审查进行优先排序的能力。该工具计算了91个药物类别的得分,这些类别总共包含962种药物。在对得分最高的类别皮质类固醇进行审查后,做出了两项药品目录变更:一种剂型从药品目录中删除,一种药物仅限门诊使用。对得分最低的类别药物佐剂进行审查后,未产生药品目录变更。本研究中描述的工具通过将具有有意义的药品目录优化机会的药物类别确定为得分最高的类别,同时将没有优化机会的类别正确确定为得分最低的类别,对年度药品目录审查工作进行了优先排序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a5f/9836755/4e8745095b31/21550417-13-02-4785_Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验